Synonym |
Thai / English name |
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : ANTITUMOR ACTIVITYSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : IMMUNOMODULATOR ACTIVITYSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : ESTERASE INCREASESolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : TUMOR NECROSING FACTOR INHIBITIONSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : WBC STIMULANTSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : NITRIC OXIDE SYNTHASE INHIBITIONSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : INTERLEUKIN-1-BETA RELEASE INHIBITIONSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : INTERLEUKIN-6 RELEASE INHIBITIONSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg
Part Used : ใบActivity : GRANULOCYTE COLONY STIMULATING FACTOR RELEASE INHIBITIONSolvent/Active Compound : 70% methanolType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntraperitonealDose/Conc.(herb) : 10 mg/kgDuration : 10 daysType of interaction : P.Kinetics & P.DynamicsInteraction with drug : Cyclophosphamide*/CPM/CTX/CYTDose/Conc.(drug) : 25 mg/kgResult : PositiveRemark : The combination of extract and CTX significantly reduced tumor volume (relative to in untreated hosts) by 73% compared to just by 52% when the extract alone was provided. Co-administration of the extract also mitigated CTX-induced toxicity, including decreases in WBC count, and in bone marrow cellularity and alpha-esterase activity. Extract treatment also attenuated any increases in serum levels of TNFalpha, iNOs, lL-1beta, lL-6, GM-CSF, and VEGF seen in tumor-bearing hosts.Note : Type experiment: BALB/c mice was randomly allocated into seven groups. Group l: normal control (treated with saline); Group ll: cyclophosphamide (CTX) only (25 mg/kg, BW) Group lll: 25 mg CTX/kg + 10 mg B. tomentosa extract/kg Group IV: DAL tumor control (mice were to be treated with the Daltion ASCites Lymphoma (DAL) induced ascites and tumor formation) Group V: DAL tumor + 25 mg CTX/kg Group Vl: DAL tumor + 10 mg B. tomentosa extract/kg Group Vlll: DAL tumor + 25 mg CTX/kg + 10 mg B. tomentosa extract/kg